Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics

Core Viewpoint - Beta Bionics, Inc. reported preliminary, unaudited financial results for Q4 2025, indicating significant growth in net sales and customer base compared to the previous year [1][6]. Financial Results - Net sales for Q4 2025 are expected to be at least $32.0 million, representing an increase of at least 56% from $20.4 million in Q4 2024 [7]. - Durable Medical Equipment (DME) channel net sales are projected to be at least $22.3 million, up at least 23% from $18.1 million in Q4 2024 [7]. - Pharmacy Benefit Plan (PBP) channel net sales are expected to reach at least $9.7 million, reflecting an increase of at least 308% compared to $2.4 million in Q4 2024 [7]. Customer Metrics - The installed customer base is anticipated to be at least 35,000 users, marking an increase of at least 128% from 15,298 in Q4 2024 [7]. - New patient starts are expected to be at least 5,581, which is an increase of at least 36% compared to 4,084 new patient starts in Q4 2024 [7]. - Approximately 69% of new patient starts are expected to come from multiple daily injections (MDI) [7]. Future Events - The company plans to report its full Q4 and full year 2025 financial results on February 17, 2026, followed by a conference call at 4:30 PM Eastern Time [4].